Literature DB >> 3965234

Effects of age and sex on piroxicam disposition.

C J Richardson, K L Blocka, S G Ross, R K Verbeeck.   

Abstract

Piroxicam kinetics were studied after a single, oral, 20-mg capsule was taken by 12 young (six women, six men) and 13 elderly (seven women, six men) healthy subjects. Plasma samples were drawn for 216 hr after dosing. Plasma protein binding was studied in vitro by equilibrium dialysis and piroxicam concentrations were measured by HPLC with ultraviolet detection. The apparent volume of distribution was smaller in elderly women (7.8 +/- 0.4 l) than in young men (11.3 +/- 0.3 l) and elderly men (10.8 +/- 0.8 l). There were no such differences when the apparent volume of distribution was normalized for total body weight. There was a strong correlation between total body weight and apparent volume of distribution in all subjects (r = 0.83). Plasma protein binding of piroxicam ranged from 98.90% to 99.54% bound and was not affected by age or sex. Piroxicam body clearance in elderly women (0.026 +/- 0.002 ml/min/kg) was approximately 33% lower than in young women (0.039 +/- 0.003 ml/min/kg). This difference was reflected in different t1/2s of 61.7 and 44.9 hr. Predicted steady-state plasma piroxicam concentrations were 5.7 micrograms/ml in young women, 5.4 micrograms/ml in young men, 5.7 micrograms/ml in elderly men, and 9.3 micrograms/ml in elderly women. The high value in elderly women results from the lower piroxicam body clearance and total body weight. Our data suggest that healthy elderly women eliminate piroxicam at a slower rate than healthy young women. The clinical significance of these data needs to be assessed in patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965234     DOI: 10.1038/clpt.1985.4

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  32 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.

Authors:  N M Davies; N M Skjodt
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

3.  Sex and age differences in the pharmacokinetics of alosetron.

Authors:  K M Koch; J L Palmer; N Noordin; J J Tomlinson; C Baidoo
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 4.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 5.  Drugs and the elderly.

Authors:  H A Bird
Journal:  Ann Rheum Dis       Date:  1990-12       Impact factor: 19.103

6.  Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers.

Authors:  L Martinez; J Sanchez; R Roser; J Garcia-Barbal; R Sagarra; A Bartlett
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

7.  A Review of Fatalities Reported as Associated with NSAID Treatment in Ontario.

Authors:  C W Gowdey; M Brennan
Journal:  Can Fam Physician       Date:  1986-09       Impact factor: 3.275

8.  Plasma tenoxicam concentrations after single and multiple oral doses.

Authors:  C Crevoisier; P Heizmann; I Forgo; U C Dubach
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

Review 9.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

10.  Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events.

Authors:  H E Rugstad; O Hundal; I Holme; O B Herland; G Husby; K E Giercksky
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.